Ann: ACTION3 IND Approved in China, page-150

Whilst there is no certainty at this time, the current indications are extremely positive in my opinion taking into account the results so far, the initial licensing agreement and the near term inflection points in terms of additional licensing agreements and initial phase 3 readouts, all at a relatively low market cap. I haven't yet found a comparable biotech on the ASX - please let me know if there is one. So I have completely recalibrated my share portfolio to build my position in DXB, selling down or exiting promising lithium holdings as well as other biotechs where I got in fairly early (including the likes of IMU where I bought in as low as 1.6c). I have been watching DBX for many years and started buying after the licensing agreement. I look forward to continuing to accumulate ahead of further positive news and assuming no adverse changes. Best wishes to all holders.